Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01414205 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01414205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01414205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
March 31, 2016
Enrollment
80 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, chronic